Details for Patent: 12,251,381

« Back to Dashboard

Which drugs does patent 12,251,381 protect, and when does it expire?

Patent 12,251,381 protects ARISTADA and ARISTADA INITIO KIT and is included in two NDAs.

This patent has ten patent family members in six countries.

Summary for Patent: 12,251,381

Title:	Aripiprazole dosing strategy
Abstract:	The present invention relates to methods of treating schizophrenia using a combination of aripiprazole, aripiprazole lauroxil, and a nanoparticle dispersion of aripiprazole lauroxil.
Inventor(s):	Lisa L. von Moltke, Peter J. Weiden, Marjie L. Hard
Assignee:	Alkermes Pharma Ireland Ltd
Application Number:	US17/665,015
Patent Claim Types: see list of patent claims	Use; Delivery;

Drugs Protected by US Patent 12,251,381

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-001	Oct 5, 2015		RX	Yes	No	12,251,381					TREATMENT OF SCHIZOPHRENIA
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-002	Oct 5, 2015		RX	Yes	No	12,251,381					TREATMENT OF SCHIZOPHRENIA
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-003	Oct 5, 2015		RX	Yes	Yes	12,251,381					TREATMENT OF SCHIZOPHRENIA

International Family Members for US Patent 12,251,381

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2019230014
Canada	3092335
China	112423754